InnoCan Pharma Corporation

As of June 30, 2026, InnoCan Pharma Corporation has 4.50M shares outstanding.

As of June 30, 2026, InnoCan Pharma Corporation maintains a current ratio of 5.25, meaning it holds 5.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.45, indicating elevated leverage, while an interest coverage ratio of -130.69 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, InnoCan Pharma Corporation posted a negative return on equity (ROE) of -21.27, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -8.95, reflecting losses generated across the asset base. The company generates approximately 3.71M in revenue per employee across its workforce of 9.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.94 indicates how many times InnoCan Pharma Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, InnoCan Pharma Corporation recorded an income tax benefit of -59,606.82 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -1.24M and -1.36M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on August 28, 2026, InnoCan Pharma Corporation's stock has declined approximately 82.31% over the past 52 weeks. The 50-day moving average sits at 15.73, while the 200-day moving average is 19.42.

Over the twelve months ended June 30, 2026, InnoCan Pharma Corporation generated 33.39M in revenue and converted that into -1.36M in net income, yielding earnings per share of -0.26. EBITDA reached -4.82M, while operating income came in at -4.87M.

As of June 30, 2026, InnoCan Pharma Corporation holds 9.08M in cash and equivalents against 2.36M in total debt, resulting in a net debt position of -6.72M. Total book value stands at 6.82M, with working capital of 11.82M providing operational flexibility.

InnoCan Pharma Corporation produced -2.17M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -26,964.99 in capital expenditures, free cash flow totaled -2.20M - equivalent to -0.49 per share.

Over the twelve months ended June 30, 2026, InnoCan Pharma Corporation posted a gross margin of 90.46, reflecting its pricing power and cost economics. The operating margin of -14.60 and net profit margin of -4.07 provide insight into operational efficiency.

InnoCan Pharma Corporation's most recent stock split took place on September 29, 2025 with a 65:1 split ratio.